Home > Boards > US Listed > Biotechs > Eloxx Pharmaceuticals Inc. (ELOX)

The company has been in the news recently.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
investora2z Member Profile
 
Followed By 10
Posts 602
Boards Moderated 0
Alias Born 02/08/13
160x600 placeholder
Eloxx Announces The Publication of Two Manuscripts on ELX-02 and It’s ERSG Library In Two Leading Journals GlobeNewswire Inc. - 10/27/2020 7:30:10 AM
Eloxx Presents Two Preclinical Posters at the 2020 North American Cystic Fibrosis Virtual Conference GlobeNewswire Inc. - 10/22/2020 8:57:31 AM
Eloxx Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on November 5, 2020 GlobeNewswire Inc. - 10/15/2020 7:00:10 AM
Globally Renowned Cystic Fibrosis Expert, Dr. Eitan Kerem, Joins Eloxx Pharmaceuticals as a Senior Consultant GlobeNewswire Inc. - 9/14/2020 10:06:20 AM
Eloxx Announces Two Preclinical Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Confer... GlobeNewswire Inc. - 8/26/2020 7:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/12/2020 7:55:55 AM
Enrollment in the U.S. Phase 2 Clinical Trial in Cystic Fibrosis Has Resumed After Being Paused in Response to the COVID-19 P... GlobeNewswire Inc. - 8/12/2020 7:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2020 8:16:56 AM
Eloxx Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results and Provides Business Update GlobeNewswire Inc. - 8/6/2020 7:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 7:51:30 AM
Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis GlobeNewswire Inc. - 8/4/2020 7:30:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/31/2020 4:11:16 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/31/2020 4:11:05 PM
Eloxx Pharmaceuticals to Present at the 40th Annual Canaccord Genuity Virtual Growth Conference on August 13th, 2020 GlobeNewswire Inc. - 7/28/2020 12:33:50 PM
Eloxx Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020 GlobeNewswire Inc. - 7/21/2020 2:17:29 PM
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Pharmacology and Experimental Therapeutics GlobeNewswire Inc. - 7/15/2020 1:08:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/17/2020 4:47:30 PM
Enrollment in Phase 2 Clinical Trial in Cystic Fibrosis Has Been Resumed in Israel and Europe After Being Paused Temporarily ... GlobeNewswire Inc. - 6/17/2020 4:01:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/26/2020 3:04:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:12:16 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:25 PM
investora2z   Monday, 11/11/13 12:11:11 PM
Re: None
Post # of 773 
The company has been in the news recently. One of the reasons is that it is going to release the cohort 3 clinical trial results soon. As mentioned by an analyst on SA, good results in the trial could be a strong catalyst for the stock. It could increase investor confidence in the company. Analysts have expressed positive opinion about the future prospects of Senesco, especially in light of its main drug candidate SNS01T. Investments by Chairman Harlan Waksal and Director Christopher Forbes at $26 equivalent in 2012 indicates their faith in company's future. Waksal has a successful track record as a biotech investor, and his investment in Senesco shows that he sees a lot of potential in SNS01T. Waksal co-founded Imclone which he ultimately sold to Eli Lilly (LLY) for $6.8 billion. SNS01T has a unique mechanism of action, and has the ability to modulate Factor 5A, a gene that regulates programmed cell death. The preclinical trial results were encouraging, and results of cohort 1 & 2 (low dosage) in multiple-myeloma patients were good. If the cohort 3 (higher dosage) results show higher efficacy and safety, then there is likely to be a major positive change in the investor outlook towards the company. The drug candidate also has use in inflammation, ischemia, and also in agriculture. The company owns numerous related patents, with applications in agriculture (increasing crop yield), programming of cell death etc. The risks of investments in development stage companies are high, though the rewards are also likely to be proportionate. The company will require funding from time to time to support the trials. Obtaining funds will squarely depend on the progress of the trials. Even if all goes well, FDA approval may take a few years. Competition in cancer field is huge, with most pharmaceutical giants having a strong presence. However, the size of the market does present a huge opportunity for the company.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences